UVA-activated 8-methoxypsoralen (PUVA) causes G2/M cell cycle arrest in Karpas 299 T-lymphoma cells

Journal of Photochemistry and Photobiology B: Biology

Volumn 85, Issue 1, 2006, Pages 39-48

  Bartošová, Jitka ^a   Kuželová, Kateřina ^a   Pluskalová, Michaela ^a   Marinov, Iuri ^a   Halada, Petr ^b   Gašová, Zdeňka ^a  

^a INSTITUTE OF HEMATOLOGY AND BLOOD TRANSFUSION   (Czech Republic)

^b INSTITUTE OF MICROBIOLOGY   (Czech Republic)

Author keywords

Apoptosis; Cdc25c; G2 M cell cycle arrest; Galectin 3; Karpas 299; PUVA

Indexed keywords

CASPASE 3; CHIMERIC PROTEIN; CYTOCHROME C; DNA FRAGMENT; GALECTIN 3; HEAT SHOCK PROTEIN; HYBRID PROTEIN; MEMBRANE ANTIGEN; METHOXSALEN; NUCLEOPHOSMIN; PEROXIREDOXIN; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLSERINE; PROTEIN KINASE; TUMOR PROTEIN;

APOPTOSIS; ARTICLE; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL MEMBRANE TRANSPORT; CELL PROLIFERATION; CELL PROTECTION; CONTROLLED STUDY; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME ACTIVITY; HUMAN; HUMAN CELL; LARGE CELL LYMPHOMA; LYMPHOMA CELL; MEMBRANE DEPOLARIZATION; MITOCHONDRIAL MEMBRANE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SECRETION; PUVA; T LYMPHOCYTE; ULTRAVIOLET A RADIATION;

1-PHOSPHATIDYLINOSITOL 3-KINASE; CASPASE 3; CELL CYCLE PROTEINS; CELL DIVISION; CELL LINE; CYTOCHROMES C; G2 PHASE; GALECTIN 3; HEAT-SHOCK PROTEINS; LYMPHOMA, T-CELL; MEMBRANE GLYCOPROTEINS; MEMBRANE PROTEINS; METHOXSALEN; MITOCHONDRIA; PEROXIDASES; PEROXIREDOXINS; PHOSPHATIDYLINOSITOL 3-KINASES; PROTEIN-TYROSINE KINASES; PUVA THERAPY; ULTRAVIOLET RAYS;

EID: 33748463095     PISSN: 10111344     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jphotobiol.2006.04.002     Document Type: Article

References (51)

1. Stern R.S., Laird N., Melski J., Parrish J.A., Fitzpatrick T.B., and Bleich H.L. Cutaneous squamous-cell carcinoma in patients treated with PUVA. N. Engl. J. Med. 310 (1984) 1156-1161
2. Lindelof B., Sigurgeirsson B., Tegner E., Larko O., Johannesson A., Berne B., Christensen O.B., Andersson T., Torngren M., and Molin L. PUVA and cancer: a large-scale epidemiological study. Lancet 338 (1991) 91-93
3. Horio T. Indications and action mechanisms of phototherapy. J. Dermatol. Sci. 23 (2000) 17-21
4. Pathak M.A., and Fitzpatrick T.B. The evolution of photochemotherapy with psoralens and UVA (PUVA): 2000 BC to 1992 AD. J. Photochem. Photobiol. B 14 (1992) 3-22
5. Edelson R., Berger C., Gasparro F., Jegasothy B., Heald P., Wintroub B., Vonderheid E., Knobler R., Wolff K., and Plewig G. Treatment of cutaneous T-cell lymphoma by extracorporeal photochemotherapy. N. Engl. J. Med. 316 (1987) 297-303
6. Oliven A., and Shechter Y. Extracorporeal photopheresis: a review. Blood Rev. 15 (2001) 103-108
7. Tambur A.R., Ortegel J.W., Morales A., Klingemann H., Gebel H.M., and Tharp M.D. Extracorporeal photopheresis induces lymphocyte but not monocyte apoptosis. Transplant. Proc. 32 (2000) 747-748
8. Berger C.L., Xu A.L., Hanlon D., Lee C., Schechner J., Glusac E., Christensen I., Snyder E., Holloway V., Tigelaar R., and Edelson R.L. Induction of human tumor-loaded dendritic cells. Int. J. Cancer 91 (2001) 438-447
9. Edelson R.L. Photopheresis: a clinically relevant immunobiologic response modifier. Ann. NY Acad. Sci. 636 (1991) 154-164
10. Gorgun G., Miller K.B., and Foss F.M. Immunologic mechanisms of extracorporeal photochemotherapy in chronic graft-versus-host disease. Blood 100 (2002) 941-947
11. Foss F.M., Gorgun G., and Miller K.B. Extracorporeal photopheresis in chronic graft-versus-host disease. Bone Marrow Transplant. 29 (2002) 719-725
12. Alcindor T., Gorgun G., Miller K.B., Roberts T.F., Sprague K., Schenkein D.P., and Foss F.M. Immunomodulatory effects of extracorporeal photochemotherapy in patients with extensive chronic graft-versus-host disease. Blood 98 (2001) 1622-1625
13. Heshmati F. Mechanisms of action of extracorporeal photochemotherapy. Transfus. Apher. Sci. 29 (2003) 61-70
14. Pathak M.A., and Joshi P.C. Production of active oxygen species by psoralens and ultraviolet radiation (320-400 nm). Biochim. Biophys. Acta 798 (1984) 115-126
15. Viola G., Facciolo L., Vedaldi D., Disaro S., Basso G., and Dall'Acqua F. Differential response of linear and angular psoralens in PUVA-induced apoptosis in HL-60 cells. Photochem. Photobiol. Sci. 3 (2004) 237-239
16. Dronkert M.L., de Wit J., Boeve M., Vasconcelos M.L., van Steeg H., Tan T.L., Hoeijmakers J.H., and Kanaar R. Disruption of mouse SNM1 causes increased sensitivity to the DNA interstrand cross-linking agent mitomycin C. Mol. Cell Biol. 20 (2000) 4553-4561
17. Enomoto D.N., Schellekens P.T., Yong S.L., ten Berge I.J., Mekkes J.R., and Bos J.D. Extracorporeal photochemotherapy (photopheresis) induces apoptosis in lymphocytes: a possible mechanism of action of PUVA therapy. Photochem. Photobiol. 65 (1997) 177-180
18. Bladon J., and Taylor P.C. Extracorporeal photopheresis induces apoptosis in the lymphocytes of cutaneous T-cell lymphoma and graft-versus-host disease patients. Br. J. Haematol. 107 (1999) 707-711
19. Aringer M., Graninger W.B., Smolen J.S., Kiener H.P., Steiner C.W., Trautinger F., and Knobler R. Photopheresis treatment enhances CD95 (fas) expression in circulating lymphocytes of patients with systemic sclerosis and induces apoptosis. Br. J. Rheumatol. 36 (1997) 1276-1282
20. Canton M., Caffieri S., Dall'Acqua F., and di Lisa F. PUVA-induced apoptosis involves mitochondrial dysfunction caused by the opening of the permeability transition pore. FEBS Lett. 522 (2002) 168-172
21. Martelli A.M., Cappellini A., Tazzari P.L., Billi A.M., Tassi C., Ricci F., Fala F., and Conte R. Caspase-9 is the upstream caspase activated by 8-methoxypsoralen and ultraviolet-A radiation treatment of Jurkat T leukemia cells and normal T lymphocytes. Haematologica 89 (2004) 471-479
22. Crawford D.F., and Piwnica-Worms H. The G(2) DNA damage checkpoint delays expression of genes encoding mitotic regulators. J. Biol. Chem. 276 (2001) 37166-37177
23. Stark G.R., and Taylor W.R. Analyzing the G2/M checkpoint. Methods Mol. Biol. 280 (2004) 51-82
24. Nurse P. Universal control mechanism regulating onset of M-phase. Nature 344 (1990) 503-508
25. Dunphy W.G. The decision to enter mitosis. Trends Cell Biol. 4 (1994) 202-207
26. King R.W., Jackson P.K., and Kirschner M.W. Mitosis in transition. Cell 79 (1994) 563-571
27. Dunphy W.G., and Kumagai A. The cdc25 protein contains an intrinsic phosphatase activity. Cell 67 (1991) 189-196
28. Gautier J., Solomon M.J., Booher R.N., Bazan J.F., and Kirschner M.W. Cdc25 is a specific tyrosine phosphatase that directly activates p34cdc2. Cell 67 (1991) 197-211
29. Strausfeld U., Labbe J.C., Fesquet D., Cavadore J.C., Picard A., Sadhu K., Russell P., and Doree M. Dephosphorylation and activation of a p34cdc2/cyclin B complex in vitro by human CDC25 protein. Nature 351 (1991) 242-245
30. Sanchez Y., Wong C., Thoma R.S., Richman R., Wu Z., Piwnica-Worms H., and Elledge S.J. Conservation of the Chk1 checkpoint pathway in mammals: linkage of DNA damage to Cdk regulation through Cdc25. Science 277 (1997) 1497-1501
31. Peng C.Y., Graves P.R., Thoma R.S., Wu Z., Shaw A.S., and Piwnica-Worms H. Mitotic and G2 checkpoint control: regulation of 14-3-3 protein binding by phosphorylation of Cdc25C on serine-216. Science 277 (1997) 1501-1505
32. St Clair S., Giono L., Varmeh-Ziaie S., Resnick-Silverman L., Liu W.J., Padi A., Dastidar J., DaCosta A., Mattia M., and Manfredi J.J. DNA damage-induced downregulation of Cdc25C is mediated by p53 via two independent mechanisms: one involves direct binding to the cdc25C promoter. Mol. Cell. 16 (2004) 725-736
33. Zhang C., Ao Z., Seth A., and Schlossman S.F. A mitochondrial membrane protein defined by a novel monoclonal antibody is preferentially detected in apoptotic cells. J. Immunol. 157 (1996) 3980-3987
34. Kuželová K., Grebeňová D., Pluskalová M., Marinov I., and Hrkal Z. Early apoptotic features of K562 cell death induced by 5-aminolaevulinic acid-based photodynamic therapy. J. Photochem. Photobiol. B 73 (2004) 67-78
35. Grebeňová D., Kuželová K., Smetana K., Pluskalová M., Cajthamlová H., Marinov I., Fuchs O., Souček J., Jarolím P., and Hrkal Z. Mitochondrial and endoplasmic reticulum stress-induced apoptotic pathways are activated by 5-aminolevulinic acid-based photodynamic therapy in HL60 leukemia cells. J. Photochem. Photobiol. B 69 (2003) 71-85
36. Grebeňová D., Kuželová K., Fuchs O., Halada P., Havlíček V., Marinov I., and Hrkal Z. Interferon-alpha suppresses proliferation of chronic myelogenous leukemia cells K562 by extending cell cycle S-phase without inducing apoptosis. Blood Cells Mol. Dis. 32 (2004) 262-269
37. Bjellqvist B., Pasquali C., Ravier F., Sanchez J.C., and Hochstrasser D.F. A nonlinear wide-range immobilized pH gradient for two-dimensional electrophoresis and its definition in a relevant pH scale. Electrophoresis 14 (1993) 1357-1365
38. Kovářová H., Halada P., Man P., Golovliov I., Kročová Z., Špaček J., Purkertová S., and Nečasová R. Proteome study of Francisella tularensis live vaccine strain-containing phagosome in Bcg/Nramp1 congenic macrophages: resistant allele contributes to permissive environment and susceptibility to infection. Proteomics 2 (2002) 85-93
39. Bai R.Y., Ouyang T., Miething C., Morris S.W., Peschel C., and Duyster J. Nucleophosmin-anaplastic lymphoma kinase associated with anaplastic large-cell lymphoma activates the phosphatidylinositol 3-kinase/Akt antiapoptotic signaling pathway. Blood 96 (2000) 4319-4327
40. Slupianek A., Nieborowska-Skorska M., Hoser G., Morrione G., Majewski M., Xue L., Morris S.W., Wasik M.A., and Skorski T. Role of phosphatidylinositol 3-kinase-Akt pathway in nucleophosmin/anaplastic lymphoma kinase-mediated lymphomagenesis. Cancer Res. 61 (2001) 2194-2199
41. Slupianek A., Hoser G., Majsterek I., Bronisz A., Malecki M., Blasiak J., Fishel R., and Skorski T. Fusion tyrosine kinases induce drug resistance by stimulation of homology-dependent recombination repair, prolongation of G(2)/M phase, and protection from apoptosis. Mol. Cell Biol. 22 (2002) 4189-4201
42. Varghese J., Khandre N.S., and Sarin A. Caspase-3 activation is an early event and initiates apoptotic damage in a human leukemia cell line. Apoptosis 8 (2003) 363-370
43. Schwerk C., and Schulze-Osthoff K. Non-apoptotic functions of caspases in cellular proliferation and differentiation. Biochem. Pharmacol. 66 (2003) 1453-1458
44. Akkari Y.M., Bateman R.L., Reifsteck C.A., Olson S.B., and Grompe M. DNA replication is required to elicit cellular responses to psoralen-induced DNA interstrand cross-links. Mol. Cell Biol. 20 (2000) 8283-8289
45. Yu F., Finley Jr. R.L., Raz A., and Kim H.R. Galectin-3 translocates to the perinuclear membranes and inhibits cytochrome c release from the mitochondria. A role for synexin in galectin-3 translocation. J. Biol. Chem. 277 (2002) 15819-15827
46. Moon B.K., Lee Y.J., Battle P., Jessup J.M., Raz A., and Kim H.R. Galectin-3 protects human breast carcinoma cells against nitric oxide-induced apoptosis: implication of galectin-3 function during metastasis. Am. J. Pathol. 159 (2001) 1055-1060
47. Takenaka Y., Fukumori T., Yoshii T., Oka N., Inohara H., Kim H.R., Bresalier R.S., and Raz A. Nuclear export of phosphorylated galectin-3 regulates its antiapoptotic activity in response to chemotherapeutic drugs. Mol. Cell Biol. 24 (2004) 4395-4406
48. Matarrese P., Tinari N., Semeraro M.L., Natoli C., Iacobelli S., and Malorni W. Galectin-3 overexpression protects from cell damage and death by influencing mitochondrial homeostasis. FEBS Lett. 473 (2000) 311-315
49. Lin H.M., Moon B.K., Yu F., and Kim H.R. Galectin-3 mediates genistein-induced G(2)/M arrest and inhibits apoptosis. Carcinogenesis 21 (2000) 1941-1945
50. Kim H.R., Lin H.M., Biliran H., and Raz A. Cell cycle arrest and inhibition of anoikis by galectin-3 in human breast epithelial cells. Cancer Res. 59 (1999) 4148-4154
51. Yoshii T., Fukumori T., Honjo Y., Inohara H., Kim H.R., and Raz A. Galectin-3 phosphorylation is required for its anti-apoptotic function and cell cycle arrest. J. Biol. Chem. 277 (2002) 6852-6857